Erratum to: Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation (United European Gastroenterology Journal, (2016), 4, (353-362), 10.1177/2050640615602571);Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation

United European Gastroenterology Journal

Volumn 4, Issue 3, 2016, Pages 353-362

  Spiller, Robin ^a   Pélerin, Fanny ^b   Cayzeele Decherf, Amélie ^b   Maudet, Corinne ^c   Housez, Béatrice ^c   Cazaubiel, Murielle ^c   Jüsten, Peter ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Lesaffre Group   (France)

^c BioFortis   (France)

Author keywords

abdominal pain; constipation; Irritable bowel syndrome; probiotics; yeast

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; BLOATING; BRISTOL STOOL SCALE QUESTIONNAIRE; CONSTIPATION; CONTROLLED STUDY; FEMALE; HUMAN; IBS SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; INTESTINAL PAIN DISCOMFORT SCORE; IRRITABLE COLON; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SACCHAROMYCES CEREVISIAE;

EID: 85006224665     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640616641615     Document Type: Erratum

References (29)

1. G.F.LongstrethW.G.ThompsonW.D.Chey. Functional bowel disorders. Gastroenterology2006; 130: 1480–1491.
2. C.CanavanJ.WestT.Card. The epidemiology of irritable bowel syndrome. Clin Epidemiol2014; 6: 71–80.
3. L.V.McFarlandS.Dublin. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol2008; 14: 2650–2661.
4. N.HoveydaC.HeneghanK.R.Mahtani. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol2009; 9: 15–15.
5. D.M.BrennerM.J.MoellerW.D.Chey. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol2009; 104: 1033–1050.
6. K.Whelan. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care2011; 14: 581–587.
7. P.MoayyediA.C.FordN.J.Talley. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut2010; 59: 325–332.
8. M.Ortiz-LucasA.TobiasP.Saz. Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis. Rev Esp Enferm Dig2013; 105: 19–36.
9. P.S.KamathS.F.PhillipsA.R.Zinsmeister. Short-chain fatty acids stimulate ileal motility in humans. Gastroenterology1988; 95: 1496–1502.
10. A.AgrawalL.A.HoughtonJ.Morris. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther2009; 29: 104–114.
11. C.RousseauxG.BouguenC.Dubuquoy. 274 Saccharomyces cerevisiae Cncm I-3856 decreases intestinal pain through PPAR alpha activation in the gut. Gastroenterology2010; 138: S–51.
12. M.BouinV.PlourdeM.Boivin. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology2002; 122: 1771–1777.
13. G.Pineton de ChambrunC.NeutA.Chau. Saccharomyces cerevisiae reduces abdominal pain in irritable bowel syndrome. Dig Liver Dis2015; 47: 119–124.
14. S.J.LewisK.W.Heaton. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol1997; 32: 920–924.
15. E.CorazziariP.BytzerM.Delvaux. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther2003; 18: 569–580.
16. J.TackS.Muller-LissnerP.Bytzer. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut2005; 54: 1707–1713.
17. D.L.PatrickD.A.DrossmanI.O.Frederick. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci1998; 43: 400–411.
18. C.KurtzmanC.Robnett. Identification and phylogeny of ascomycetous yeasts from analysis of nuclear large subunit (26S) ribosomal DNA partial sequences. Antonie Van Leeuwenhoek1998; 73: 331–371.
19. C.P.KurtzmanC.J.Robnett. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5' end of the large-subunit (26S) ribosomal DNA gene. J Clin Microbiol1997; 35: 1216–1223.
20. CEN/TS 15790:2008.Animal feeding stuffs: PCR typing of probiotic strains of Saccharomyces cerevisiae (yeast)
21. D.A.DrossmanW.D.CheyJ.F.Johanson. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome: results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther2009; 29: 329–341.
22. J.M.JohnstonC.B.KurtzJ.E.Macdougall. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology2010; 139: 1877–1886.
23. J.C.DebongnieS.F.Phillips. Capacity of the human colon to absorb fluid. Gastroenterology1978; 74: 698–703.
24. L.MarcianiE.F.CoxC.L.Hoad. Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology2010; 138: 469–477.
25. S.E.PritchardL.MarcianiK.C.Garsed. Fasting and postprandial volumes of the undisturbed colon: normal values and changes in diarrhea-predominant irritable bowel syndrome measured using serial MRI. Neurogastroenterol Motil2014; 26: 124–130.
26. I.PosserudP.O.StotzerE.S.Bjornsson. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut2007; 56: 802–808.
27. U.C.GhoshalD.SrivastavaU.Ghoshal. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol2014; 26: 753–760.
28. M.PimentelA.LemboW.D.Chey. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med2011; 364: 22–32.
29. E.P.HalmosV.A.PowerS.J.Shepherd. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology2014; 146: 67–75.